Provided by Tiger Fintech (Singapore) Pte. Ltd.

iBio

0.8470
+0.089411.80%
Post-market: 0.8300-0.0170-2.01%19:57 EDT
Volume:979.33K
Turnover:817.36K
Market Cap:8.36M
PE:-0.33
High:0.8951
Open:0.7600
Low:0.7585
Close:0.7576
Loading ...

IBio Inc. Stock Falls Monday, Still Outperforms Market

Dow Jones
·
28 Jan

IBio Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
25 Jan

IBio Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
23 Jan

IBio Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
22 Jan

IBio Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
16 Jan

IBio Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
14 Jan

iBio director buys $500K in common stock

TIPRANKS
·
14 Jan

Ibio Announces New Investments From Board Members and Officers

THOMSON REUTERS
·
13 Jan

Press Release: iBio Announces New Investments from Board Members and Officers

Dow Jones
·
13 Jan

IBio Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
11 Jan

IBio Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
09 Jan

iBio, AstralBio announce development of antibody inhibiting Activin E

TIPRANKS
·
07 Jan

Ibio Discovers Novel Antibody Targeting Activin E in Collaboration With Astralbio

THOMSON REUTERS
·
07 Jan

iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

GlobeNewswire
·
07 Jan

IBio Inc. Stock Rises Monday, Still Underperforms Market

Dow Jones
·
07 Jan

iBio Expands Pipeline with New Antibody Agreement

TipRanks
·
03 Jan

IBio Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
03 Jan

Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform

Benzinga
·
02 Jan

Ibio Inc: Plans to Enter Into Clinical Investigation in Obesity and Cardiometabolic Disorders in 2026

THOMSON REUTERS
·
02 Jan

Ibio Expands Cardiometabolic and Obesity Program With Anti-Myostatin Antibody Discovered Using Its Proprietary Platform, in-Licensed From Astralbio

THOMSON REUTERS
·
02 Jan